Efficacy of SBP-101, in combination with gemcitabine and nab-paclitaxel, in first-line treatment of metastatic pancreatic ductal adenocarcinoma

被引：0
|
作者：
Kotasek, Dusan
Nagrial, Adnan
Lumba, Sumit
Tebbutt, Niall C.
George, Thomas J.
Smith, Sheri Lynn
Gagnon, Suzanne
Cullen, Michael T.
Walker, Michael J.
机构：
[1] Univ Adelaide, Adelaide, SA, Australia
[2] Blacktown Hosp, Canc & Haematol Ctr, Blacktown, NSW, Australia
[3] John Flynn Private Hosp, Canc & Haematol Ctr, Tugun, Qld, Australia
[4] Heidelberg Repatriat Hosp, AfA A A, Olivia Newton John Canc & Wellness Ctr, Heidelberg, Vic, Australia
[5] Univ Florida, Hlth Canc Ctr, Gainesville, FL USA
[6] Courante Oncol, Excelsior, MN USA
[7] Sun BioPharma Inc, Jamestown, RI USA
[8] Sun BioPharma Inc, Waconia, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
710
引用
收藏
页数：2
相关论文
共 50 条
  • [21] EFFICACY AND SAFETY OF NAB-PACLITAXEL IN COMBINATION WITH GEMCITABINE FOR METASTATIC PANCREATIC CANCER
    You, Min Su
    Ryu, Ji Kon
    Kang, Jinwoo
    Choi, Jin Ho
    Choi, Young Hoon
    Huh, Gunn
    Paik, Woo Hyun
    Lee, Sang Hyub
    Kim, Yong-Tae
    GASTROENTEROLOGY, 2018, 154 (06) : S285 - S285
  • [22] Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma
    Perri, Giampaolo
    Prakash, Laura
    Qiao, Wei
    Varadhachary, Gauri R.
    Wolff, Robert
    Fogelman, David
    Overman, Michael
    Pant, Shubham
    Javle, Milind
    Koay, Eugene J.
    Herman, Joseph
    Kim, Michael
    Ikoma, Naruhiko
    Tzeng, Ching-Wei
    Lee, Jeffrey E.
    Katz, Matthew H. G.
    JAMA SURGERY, 2020, 155 (09) : 832 - 839
  • [23] Avutometinib/defactinib and gemcitabine/nab-paclitaxel combination in first-line metastatic pancreatic ductal adenocarcinoma: Initial safety and efficacy of phase 1b/2 study (RAMP 205).
    Lim, Kian-Huat
    Spencer, Kristen Renee
    Safyan, Rachael A.
    Picozzi, Vincent J.
    Varghese, Anna M.
    Siolas, Despina
    Perez, Kimberly
    Clift, Sheena
    Denis, Louis J.
    Bhambhani, Vijeta
    Hill, Stacey
    Pachter, Jonathan A.
    Pultar, Philippe
    Hidalgo, Manuel
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Nab-paclitaxel/S-1(AS) versus nab-paclitaxel/gemcitabine(AG) for first-line chemotherapy in advanced pancreatic ductal adenocarcinoma (aPDAC): A retrospective analysis of efficacy and safety.
    Zong, Yuan
    Peng, Zhi
    Lu, Ming
    Wang, Xicheng
    Zhou, Jun
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [25] Efficacy and toxicity comparison of nab-paclitaxel plus S-1 and nab-paclitaxel plus gemcitabine as first-line chemotherapy for metastatic pancreatic cancer
    Guo Xi
    Xu Yaolin
    Ji Yuan
    Fan Yue
    Wang Dansong
    Jin Dayong
    Zhuang Rongyuan
    Wu Lili
    Lou Wenhui
    Zhou Yuhong
    Department of Medical Oncology
    Department of General Surgery
    Department of Pathology
    Department of Traditional Chinese Medicine
    Department of Radiotherapy
    胰腺病学杂志（英文）, 2020, 03 (01) : 35 - 41
  • [26] Evaluation of Human Pancreatic Cancer Cell Viability Following Administration of SBP-101 in the Presence and Absence of Gemcitabine and Nab-Paclitaxel
    Baker, C.
    Arora, S.
    Gagnon, S.
    Cullen, M.
    Shah, A.
    PANCREAS, 2015, 44 (08) : 1360 - 1361
  • [27] A phase Ib study evaluating olaratumab in combination with nab-paclitaxel and gemcitabine in first-line treatment of metastatic pancreatic cancer.
    Pelzer, Uwe
    Bendell, Johanna C.
    Womack, Mark S.
    Bahary, Nathan
    Macarulla, Teresa
    Borazanci, Erkut Hasan
    Levy, Donna Elise
    Mo, Gary
    Ramage, Samuel Cowan
    Garrido-Laguna, Ignacio
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [28] Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine
    Di Costanzo, Francesco
    Di Costanzo, Federica
    Antonuzzo, Lorenzo
    Mazza, Ernesto
    Giommoni, Elisa
    CANCERS, 2023, 15 (02)
  • [29] Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment
    Pretta, Andrea
    Ziranu, Pina
    Giampieri, Riccardo
    Donisi, Clelia
    Cimbro, Erika
    Spanu, Dario
    Lai, Eleonora
    Pecci, Federica
    Balconi, Francesca
    Lupi, Alessio
    Pozzari, Marta
    Persano, Mara
    Murgia, Sara
    Pusceddu, Valeria
    Puzzoni, Marco
    Berardi, Rossana
    Scartozzi, Mario
    DIGESTIVE AND LIVER DISEASE, 2023, 55 (05) : 655 - 660
  • [30] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study
    Yuan Zong
    Jiajia Yuan
    Zhi Peng
    Ming Lu
    Xicheng Wang
    Lin Shen
    Jun Zhou
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 1529 - 1536
12345